| Business Summary | | Barr
Laboratories,
Inc.
is
a
specialty
pharmaceutical
company
engaged
in
the
development,
manufacture
and
marketing
of
generic
and
proprietary
prescription
pharmaceuticals.
The
majority
of
the
Company's
current
products
represent
generic
forms
of
brand
pharmaceutical
products.
Among
the
Company's
key
generic
products
are
Tamoxifen
Citrate,
Hydroxyurea,
Methotrexate
and
Megestrol
Acetate
for
oncology,
Warfarin
Sodium
and
Dipyridamole
for
cardiovascular
functions,
Medroxyprogesterone
Acetate,
Danazol,
Estradiol
and
Estropipate
for
female
healthcare
and
Naltrexone,
Meperidine,
Oxy-APAP,
Diazepam
and
Trazodone
for
other
functions. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Barr
Laboratories
is
a
pharmaceutical
company
engaged
in
the
development,
manufacture
and
marketing
of
generic
and
proprietary
prescription
pharmaceuticals.
For
the
fiscal
year
ended
6/30/01,
sales
rose
16%
to
$509.7
million.
Net
income
rose
41%
to
$62.5
million.
Revenues
reflect
higher
sales
of
Tamoxifen,
ViaSpan,
Trazodone,
Fluvoxamine
and
Warfarin.
Net
income
also
reflects
improved
gross
and
operating
margins,
higher
interest
income
and
a
$6.7
million
gain
on
the
sale
of
Galen
Holdings. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Bruce Downey, 52 Chairman,
CEO | $935K | -- | Paul Bisaro, 39 Pres,
COO, Sec., Director | 405K | $704K | Edwin Cohen, 68 Vice
Chairman | -- | -- | William McKee, 39 Sr.
VP, CFO and Treasurer | -- | -- | Martin Zeiger, 63 Sr.
VP, Strategic Bus. Devel. and Gen. Counsel | -- | -- | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|